A new AIDS vaccine that combines two experimental therapies has shown promise in monkeys. The animals were given a vaccine developed by Johnson & Johnson ($JNJ) subsidiary Crucell combined with a booster created by the U.S military and the National Institute of Allergy and Infectious Diseases, and exposed to a highly immune-resistant strain of simian immunodeficiency virus (SIV), which is similar to AIDS. Those monkeys that received the combination vaccine/booster were up to 83% less likely to contract the virus, although animals that were repeatedly exposed to the disease eventually contracted SIV. The findings were published in the online edition of the journal Nature. Report | Article